Resurrect Bio banked €8.8 million ($10.3 million) in a Series A funding round to enhance its plant disease resistance technology. The investment was led by Corteva Catalyst, with participation from Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder. This close follows an initial €6.8 million tranche raised earlier in 2026, bringing the total capital raised since the company's inception to approximately $12.4 million.
The London-based startup develops disease-resistant crops by reactivating the natural immune systems of plants. Using its FloraFold AI platform, the company predicts interactions between plant and pathogen proteins to identify where a crop's internal defences have been weakened. By repairing these specific mechanisms, the company provides the seed industry with a sustainable alternative to chemical crop protection treatments.
Spun out of The Sainsbury Laboratory in Norwich in 2022, the company uses high-throughput functional biology to validate its AI predictions. These platforms are designed to significantly reduce the time required to move from discovery to the deployment of resistant traits in commercial crop varieties. The new capital will be used to grow the team and deepen its discovery and reactivation platforms.
Resurrect Bio is currently collaborating with Corteva Agriscience to develop disease resistance specifically for corn. The company's expansion into AI-driven trait discovery reflects a broader shift towards genomic solutions as a means of securing global food networks against the limitations of conventional breeding and chemical inputs.
Originally reported by EU-Startups Daily.